{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:23:36Z","timestamp":1790709816893,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,1,1]]},"abstract":"<jats:p> PURPOSE: The aim of the present phase II study was to evaluate the efficacy of the paclitaxel, ifosfamide, and cisplatin (PIC) combination in relapsed small-cell lung cancer (SCLC). <\/jats:p><jats:p> PATIENTS AND METHODS: Eligible patients were those with SCLC who had progressed or relapsed after therapy with carboplatin and etoposide (with or without chest radiotherapy). The PIC regimen consisted of paclitaxel 175 mg\/m<jats:sup>2<\/jats:sup> on day 1, ifosfamide 5 g\/m<jats:sup>2<\/jats:sup> divided over days 1 and 2, and cisplatin 100 mg\/m<jats:sup>2<\/jats:sup> divided over days 1 and 2; PIC was given every 21 days with granulocyte colony-stimulating factor support. <\/jats:p><jats:p> RESULTS: Thirty-three patients (30 men and three women) were entered onto the study (median age, 62 years [range, 55 to 70 years]; median performance status, 1 [range, 0 to 2]). Metastatic sites at study entry included the lymph nodes (n = 13 patients), bone (n = 9), liver (n = 5), brain (n = 6), lung nodules (n = 8), adrenal glands (n = 9), and other (n = 2) Responses included eight complete remissions and 16 partial remissions (overall response rate, 73% [24 of 33 patients]). Five patients had stable disease and two had progressive disease. Median time to progression and overall survival were 21 and 28 weeks, respectively. The 1-year survival rate was 12%, with two patients alive without evidence of disease at 76 and 104 weeks since PIC initiation. Grade 3 and 4 toxicities included neutropenia in 30 patients (24 [73%] developed grade 4 neutropenia [ &lt; 5 days]) and febrile neutropenia in six patients (18%); grade 3 or 4 thrombocytopenia was seen in nine patients (27%) . No grade 3 neuropathy was observed; grade 1 or 2 CNS toxicity was seen in five patients, there was no renal toxicity, grade 2 myalgias were seen in nine patients, grade 2 diarrhea was seen in one patient, and grade 3 nausea or vomiting was seen in seven patients. There were no treatment-related deaths. <\/jats:p><jats:p> CONCLUSION: In the present phase II study, the PIC combination seemed highly active and tolerable in patients with relapsed SCLC when it was administered as second-line treatment. Given the present experience, an evaluation of the PIC regimen as front-line treatment of SCLC is planned. <\/jats:p>","DOI":"10.1200\/jco.2001.19.1.119","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:54:02Z","timestamp":1487919242000},"page":"119-126","source":"Crossref","is-referenced-by-count":59,"title":["Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin  as Second-Line Treatment in Relapsed Small-Cell  Lung Cancer"],"prefix":"10.1200","volume":"19","author":[{"given":"Christos","family":"Kosmas","sequence":"first","affiliation":[{"name":"From the Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital, and Oncology Unit, Department of Pathophysiology, Laikon General Hospital, Athens University School of Medicine, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas B.","family":"Tsavaris","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital, and Oncology Unit, Department of Pathophysiology, Laikon General Hospital, Athens University School of Medicine, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos A.","family":"Malamos","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital, and Oncology Unit, Department of Pathophysiology, Laikon General Hospital, Athens University School of Medicine, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vadiaka","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital, and Oncology Unit, Department of Pathophysiology, Laikon General Hospital, Athens University School of Medicine, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Koufos","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital, and Oncology Unit, Department of Pathophysiology, Laikon General Hospital, Athens University School of Medicine, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-082711","doi-asserted-by":"crossref","unstructured":"Johnson  DH:   Treatment of relapsed small cell lung cancer.   Lung Cancer 11:  142,1994-143,     (suppl 1)","DOI":"10.1016\/0169-5002(94)92091-5"},{"key":"R2-082711","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.54"},{"key":"R3-082711","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(88)90242-8"},{"key":"R4-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.927"},{"key":"R5-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2594"},{"key":"R6-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1615"},{"key":"R7-082711","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.0919"},{"key":"R8-082711","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000815)89:4<774::AID-CNCR9>3.0.CO;2-5"},{"key":"R9-082711","unstructured":"Zaniboni  A,   Meriggi  F,   Rizzi  A,  et al:  Paclitaxel, ifosfamide, and carboplatin for the treatment of stages IIIB and IV non-small cell lung cancer.   Semin Oncol 24:  70,1997-72,     (suppl 12)"},{"key":"R10-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2722"},{"key":"R11-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1325"},{"key":"R12-082711","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008461408626"},{"key":"R14-082711","doi-asserted-by":"crossref","unstructured":"Kaplan  EL,   Meier  P:   Non-parametric estimation from incomplete observations.   J Am Stat Assoc 53:  457,1959-481,","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R15-082711","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R16-082711","doi-asserted-by":"crossref","unstructured":"Postmus  PE,   Smit  EF,   Kirkpatrick  A,  et al:  Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer:   A phase II study of the EORTC Lung Cancer Cooperative Group.   Eur J Cancer 29A:  204,1993-207,","DOI":"10.1016\/0959-8049(93)90176-G"},{"key":"R17-082711","unstructured":"Parker  RJ,   Dabholkar  MD,   Lee  KB,  et al:  Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.   J Natl Cancer Inst Monogr 15:  83,1993-88,"},{"key":"R18-082711","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<561::AID-CNCR19>3.0.CO;2-#"},{"key":"R19-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.2010"},{"key":"R20-082711","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90419-X"},{"key":"R21-082711","unstructured":"Greco  FA,   Hainsworth  JD:   One hour paclitaxel infusion schedule:   A phase I\/II comparative trial.   Semin Oncol 22:  118,1995-123,"},{"key":"R22-082711","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050669"},{"key":"R23-082711","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050853"},{"key":"R24-082711","unstructured":"Reed  E,   Kohn  EC,   Sarosy  G,  et al:  Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer:   Molecular rationale and early clinical results.   Semin Oncol 22:  90,1995-96,     (suppl 6)"},{"key":"R25-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1209"},{"key":"R26-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1794"},{"key":"R27-082711","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"R28-082711","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1179::AID-CNCR23>3.0.CO;2-I"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.1.119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:38:43Z","timestamp":1653514723000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.1.119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,1]]}},"alternative-id":["10.1200\/JCO.2001.19.1.119"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.1.119","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,1]]}}}